October 4, 2022
Life Sciences
  • Federal Trade Commission (FTC) Chair Lina Khan said the agency is considering all its tools, including law enforcement or market-wide rulemaking, as it scrutinizes the business practices of pharmacy benefit managers (PBMs). When asked whether existing antitrust laws could be used against PBMs, Khan cited two, including the Robinson-Patman Act of 1936, which the agency is now looking at whether it can be applicable in cases of commercial bribery and rebating practices after it was regularly deployed by the FTC in the 1950s and 1960s. (Article here)